Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central nervous method, conolidine modulates alternate molecular targets. A Science Improvements examine identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7,

Although scientists are mindful of the analgesic outcomes of comparable compounds, it's been complicated to analyze conolidine considering that there isn't sufficient of it readily available from normal sources. It would make up just 0.00014% from the bark of T. divaricataWe demonstrated that, in distinction to classical opioid receptors,